- Price
- $27.60
- Day
- -0.14%
- Mkt Cap
- $157.30B
- 52W Range
- $23.58 – $29.21
- Volume
- 73.58M
- Beta
- 0.30
Find a company by name or ticker and open its page
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
Pfizer has made significant progress in addressing some of its challenges. However, the company still has a rocky road ahead.
Read full article
Pfizer (PFE +0.07%) has experienced unprecedented circumstances in the previous decade.
Read full article
They have a knack for increasing their dividends even when facing challenges.
Read full article
Pfizer's free cash flow is not covering its dividend, and the company faces a patent cliff. Energy Transfer is one of the biggest beneficiaries of strong natural demand coming from the AI data center build-out.
Read full article
Pfizer has raised its dividend every year for over a decade, then something changed. Before you count on that 6% yield, find out what the payout's own behavior is quietly signaling about the company's financial confidence.
Read full article
Pfizer's management remains firmly committed to maintaining the dividend. The company's growth portfolio is performing well.
Read full article
The yield you chase to replace a six-figure salary determines far more than how much capital you need. It quietly sets your exposure to leverage, dividend cuts, and an NAV that can quietly bleed out before you notice.
Read full article
Where you hold a high-yield dividend stock matters almost as much as which one you pick, and for ordinary-income payers like BDCs and REITs, the wrong account quietly erodes a portion of every distribution before it ever compounds.
Read full article
Pfizer, Novartis, Janux Therapeutics and Candel Therapeutics offer varied prostate-cancer exposure, with established drugs and clinical or regulatory catalysts.
Read full article
Bank of America Corp DE purchased a new stake in Pfizer Inc. (NYSE: PFE) during the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 43,588,109 shares of the biopharmaceutical company's stock, valued at approximately $1,049,602,000. Bank of America Corp DE owned about
Read full article
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) invites investors and the general public to listen to a webcast of a discussion with Alexandre de Germay, Chief International Commercial Officer, Executive Vice President, at the J.P. Morgan U.S. All Stars 2026 Conference on Tuesday, September 22, 2026 at 11:50 a.m. BST. To listen to the webcast, visit our web site at www.pfizer.com/investors. Information on accessing and registering for the webcast will be available at www.pfizer.com/investors.
Read full article
Recently, Zacks.com users have been paying close attention to Pfizer (PFE). This makes it worthwhile to examine what the stock has in store.
Read full article